Immunocore Holdings Limited is a pioneering biotechnology company headquartered in Abingdon, UK, dedicated to the development of cutting-edge immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary T cell receptor technology, Immunocore aims to harness and amplify the body’s immune response, driving forward transformative treatment options with the potential to significantly enhance patient outcomes. The company boasts a solid pipeline of clinical programs and strategic collaborations that position it as a key player in the dynamic immunotherapy sector, poised for substantial growth and impact within this rapidly advancing field.